Home
  • About Diabetic
    Foot Causes
    • Diabetic Foot Causes
    • Diabetic Foot Symptoms
    • Diabetic Foot Complications
    • Diabetic Foot Treatment
    • Preventing Diabetic Foot
    • Educational Handbook
  • Selecting
    Fespixion
    • Development Process
    • Clinical Trials
    • Mechanism
    • Literature Review
    • Quality Certification
  • Starting
    Fespixion
    • Indications and Dosagen
    • Drug Safety
    • Package Insert
    • Usage Videos
  • Stories
    • Popular Articles
    • Popular Videos
  • About
    Oneness
    • Company Introduction
    • Core Values and Business Philosophy
    • Corporate Sustainable Responsibility
  • Contact Us
  • 繁
  • 简
  • EN

Popular Articles

2023-11-13
DRUG TIMES
China's first Class 1.1 natural new drug approved! The annual demand for diabetic foot ulcers reaches RMB tens of billions, and many pharmaceutical companies are actively seeking collaboration opportunities
2023-10-03
diaTribe Learn
New Cream Could Be Valuable Addition to Diabetic Foot Ulcer Treatment
2023-07-08
The Star
Health Ministry approves the first natural products with therapeutic claims, says Health DG
2023-01-05
Enterprise Asia
Oneness Biotech Co., Ltd.'s FESPIXON® Honored at the International Innovation Awards 2022
2022-09-29
INF News
The first in the world!New drug for diabetic foot ulcer: research and development code "ON101"
2022-07-16
Diabetes In Control
Diabetes: Better Relief for Ulcerated Feet On the Horizon
2021-10-09
Medivizor
How effective is a new macrophage-regulating drug for wound healing in patients with diabetic foot ulcers?
2021-10-07
Diabetes Self-management
New Topical Drug Helps Foot Ulcers Heal in Clinical Trial
  • ‹
  • 1
  • 2
  • ›
Home
icon Address:35F., No. 66, Sec. 1, Zhongxiao W. Rd., Zhongzheng Dist., Taipei City, Taiwan (R.O.C.)
icon Phone:+886 (0)2-2703-1098
icon Fax:+886 (0)2-2703-1200
icon Facebook
icon Contact Us
icon Linkedln
Privacy Policy Copyright © Oneness Biotech Co., Ltd.. All Rights Reserved.